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Konrad Thorsteinsson, Erik Olseń, Eneas Schmidt, Hudson Pace,*,⊥ and Marta Bally*,⊥
Cite This: Anal. Chem. 2020, 92, 15336−15343 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Research in the field of extracellular vesicles is
rapidly expanding and finding footholds in many areas of medical
science. However, the availability of methodologies to quantify the
concentration of membrane material present in a sample remains
limited. Herein, we present a novel approach for the quantification
of vesicle material, specifically the quantification of the total lipid
membrane surface area, found in a sample using Förster resonance
energy transfer (FRET). In this assay, sonication is used to drive
the fusion between vesicles in the sample to be quantified and
liposomes containing a pair of FRET fluorophores. The change in
emission spectrum upon vesicle fusion is directly related to the total
membrane surface area of the sample added, and a calibration curve
allows for the quantification of a variety of vesicle species, including
enveloped viruses, bacterial outer membrane vesicles, and mammalian extracellular vesicles. Without extensive optimization of
experimental parameters, we were able to quantify down to ∼109 vesicles/mL, using as little as 60 μL of the sample. The assay
precision was comparable to that of a commercial nanoparticle tracking analysis system. While its limit of detection was slightly
higher, the FRET assay is superior for the detection of small vesicles, as its performance is vesicle-size-independent. Taken together,
the FRET assay is a simple, robust, and versatile method for the quantification of a variety of purified vesicle samples.
■ INTRODUCTION
Extracellular vesicles (EVs) produced by both eukaryotic and
prokaryotic cells have been found to mediate intercellular
communication in a variety of biological contexts. Within
humans, EVs produced by our own cells have been shown, for
example, not only to modulate immune response regula-
tion,1−3 inflammation,4−6 or tissue regeneration7,8 but also to
be involved in disease propagation.9−11 Bacterial EVs also
contribute to modulating human physiology, both those
produced by commensal bacteria in our digestive systems
and those produced by pathogenic bacteria to propagate
disease.12 Enveloped viruses represent yet another class of lipid
bilayer-encapsulated biological particles, responsible for
generating a variety of diseases in humans and other organisms.
Liposomes are artificially produced vesicles that have been
widely investigated as drug delivery vehicles.13−15 As outlined
above, biological and synthetic vesicles are associated with a
broad spectrum of research areas, all of which are currently
hindered by the underdevelopment of methods to quantify
lipid vesicle concentrations in a robust and versatile manner.
Traditionally, vesicle quantification has been performed
using methods relying on the quantification of specific
biomolecular constituents of the vesicles. Indeed, the
concentration of an EV sample is often reported in terms of
total protein content, given in protein mass per unit volume;16
for virus particles, the quantification of oligonucleotides can be
used;17 while for liposomes, phosphorus quantification is an
extremely robust approach to determine the number of
phospholipids in the sample. A drawback of such approaches
is that they only provide an indirect measure of the particle
content, in particular, since the protein/particle or oligonucleo-
tide/particle ratio is often unknown and may vary greatly
among different vesicle types and sample batches. As a
complement to biomolecular quantification approaches,
methods allowing for the determination of particle concen-
trations, given in particles/volume, have been developed within
the last decade. In particular, nanoparticle tracking analysis
(NTA),18 which allows for the visualization of the light
scattered by individual vesicles upon laser illumination, has
gained in popularity for vesicle characterization.16,19−21 With
this method, vesicle numbers can be quantified by particle
counting and their size estimated upon tracking of their
Brownian motion. A constraint of this method is that the
relatively weak scattering properties of vesicles in solution limit
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the detection to those with diameters above 50−70 nm.19 This
is not sufficient to detect the smallest vesicle populations that
may have characteristic diameters down to 30 nm.22
Herein, we propose an alternative methodology for
quantifying vesicle samples whose sensitivity is not dependent
on vesicle size. Rather than using specific biomolecular targets
(e.g., protein or phospholipids), our assay quantifies the total
surface area (TSA) of membrane material (i.e., all membrane
components) in the sample using a Förster resonance energy
transfer (FRET)-based assay. In our assay design, inspired by
liposome-based methods traditionally used to detect mem-
brane fusion,23,24 sonication is used to drive the fusion of
liposomes containing a pair of fluorophore−lipid conjugates
subject to FRET with the sample vesicles to be quantified
(Figure 1a). Upon fusion, the intermolecular distance of the
FRET pair increases, resulting in a decrease in acceptor
emission and an increase in donor emission (Figure 1B),
whereby the change in the emission spectrum of the fused
vesicles is directly related to the amount of sample vesicles
added.
■ MATERIALS AND METHODS
Materials. All materials unless stated otherwise were
purchased from commercial sources. Lipids used in this
project were 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (Rhod-PE, Ex/Em: 560/
583 nm), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-PE, Ex/Em: 460/
535 nm). Chloroform was used as a solvent for all lipids. All
lipids were obtained from Avanti Polar Lipids Inc. (Alabama).
Chloroform, potassium antimonyl tartrate trihydrate
(C8H4K2O12Sb2·3H2O), ammonium heptamolybdate tetrahy-
drate ((NH4)6Mo7O24·4H2O), and a phosphorus standard
solution (0.65 M) were obtained from Sigma-Aldrich
(Darmstadt, Germany). 4-(2-Hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES), sulfuric acid, and ascorbic acid were
obtained from Merck (New Jersey), while phosphate-buffered
saline (PBS) tablets were obtained from Medicago AB
(Uppsala, Sweden) and NaCl was obtained from VWR
Chemicals (Leuven, Belgium). All water samples used in the
experiments were deionized and filtered using a Milli-Q system
(Millipore, France).
Outer membrane vesicles (OMVs) from an Escherichia coli
mutant with truncated lipopolysaccharides (hldE strain
(RN102)) were kindly provided by Madeleine Ramstedt
(Department of Chemistry, Umeå University) and produced as
previously described.25 Herpes simplex virus type 2 (HSV-2)
of the strain 333 (wt-333)26 was produced by infecting GMK
AH1 cells, followed by purification through a three-step
discontinuous sucrose gradient as previously described.27,28
The virus was kindly provided by Tomas Bergström (Depart-
ment of Infectious Diseases, University of Gothenburg). The
eukaryotic extracellular vesicles, hereforth referred to as EVs,
were produced by a rat oligodendroglial cell line, OLN-93, as
previously described29 and kindly provided by Jonathan
Gilthorpe (Department of Integrative Medical Biology, Umeå
University).
Vesicle Preparation. All liposomes were prepared using
the lipid hydration and extrusion method. Appropriate
amounts of lipids dissolved in chloroform were added to a
round-bottom flask. The chloroform was first evaporated under
a constant airflow while rotating the flask at an angle to form a
homogeneous lipid film on the bottom of the flask. The flask
was then left under airflow for 1.5 h to ensure that all of the
chloroform evaporates. After drying, the lipid film was
hydrated with HEPES-buffered saline (HBS), consisting of
10 mM HEPES and 150 mM NaCl, with pH = 7.4 and
extruded using a mini extruder (Avanti Polar Lipids Inc.). The
100% POPC liposomes used for illustrating the size-
independence of the FRET-assay were prepared by first
freeze−thawing the vesicle solution five times in liquid
nitrogen. The liposome solution was then extruded either 31
times through a 400 nm polycarbonate membrane or 11 times
through a 100 nm membrane followed by 31 times through a
30 nm membrane. All other vesicles were extruded 11 times
through a polycarbonate membrane with 100 nm pores
without freeze−thawing cycling. The FRET liposomes were
composed of 99 mol % POPC, 0.5 mol % Rhod-PE, and 0.5
mol % NBD-PE. The liposomes used to establish the
calibration curve were made of 100% POPC.
Phosphorus Assay. To quantify the phospholipid content
of the liposome stocks prepared as described above and to
account for possible lipid losses during the extrusion
procedure, a phosphorus assay was used. The assay is based
on the molybdenum blue method30,31 and was performed as
described by Paraskova et al.32 with the modification that
digestion was performed solely by dry ashing for at least 4 h at
550 °C. Calcination was performed in a Carbolite CWF 1200
furnace (Carbolite Gero Limited, Hope Valley, U.K.).
Absorbance at 882 nm was measured three times to obtain
an average in the multimode microplate reader Varioskan Flash
(Thermo Fisher Scientific). The band width was 5 nm, and the
measurement time was 100 ms. The calibration curves for the
assay were established using a 0.65 mM phosphorus standard
solution (Sigma-Aldrich). The calibration curve was estab-
lished without calcinating the standard solution, as a
Figure 1. Schematic representation of the FRET assay. (A) FRET liposomes fuse with unlabeled sample vesicles to be quantified, thereby reducing
the surface density of fluorophores. Fusion is facilitated by sonication. (B) Change in the emission spectrum of the fused vesicles as a function of
sample vesicle percentage. Excitation wavelength: 460 nm. The sample fraction is the ratio of sample vesicles in the sample.
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preliminary test showed no difference in the absorbance
between calcinated and uncalcinated standard solutions (data
not shown).
Sonication Procedure for Lipid Mixing. A bath
sonicator (ultrasonic frequency: 37 kHz; ultrasonic power
(effective/max): 140/560 W; Elmasonic S40H, Germany) was
used to induce vesicle fusion. Unless stated otherwise, the
FRET assay was performed as follows: FRET liposomes and
either calibration liposomes or sample vesicles were mixed
together keeping the concentration of FRET liposomes
constant at 4.3 × 10−8 mol/mL of lipids (1 μL of 1 mg/mL
added), corresponding to a surface area concentration (SAC)
of 82.5 × 1014 nm2/mL of FRET liposomes, while the
concentration of sample vesicles was varied accordingly to
bring the mixture to a total of 60 μL. This vesicle mixture was
sonicated in a prewarmed, degassed, and half-full Elmasonic
S40H bath sonicator making sure to place the sample in
vibrational “hotspots”, where the vibrations are the strongest.
Water temperature was kept constant (±1 °C) using small
additions of ice.
Spectrofluorimetry. For fluorescence measurements, 50
μL of the sonicated samples was mixed with 50 μL of buffer in
the well of a black-bottomed NUNC plate (634-0006, Thermo
Scientific) and scanned for fluorescence spectra with the
multimode microplate reader Varioskan Flash (Thermo Fisher
Scientific). To acquire an emission spectrum, the sample was
excited at 460 nm with an emission scan between 490 and 650
nm. The excitation bandwidth was 12 nm, and the dynamic
range was set to “Medium Low”. The measurement time was
100 ms. In all measurements, the background signal of pure
buffer was subtracted from the FRET signal. Rhodamine and
NBD have listed spectral intensity peaks at 583 and 535 nm,
respectively. However, we observed the intensity peaks at 588
nm for rhodamine and 535 nm for NBD. These wavelengths
were therefore used to estimate the respective peak intensity
values and to calculate the FRET signal (ratio of the
rhodamine and NBD peaks).
Nanoparticle Tracking Analysis. Nanoparticle tracking
analysis (NTA) measurements were performed with a
ZetaView PMX 110 NTA device from Particle Metrix
GmbH (Inning am Ammersee, Germany). The device was
calibrated with 102 nm standard beads from the manufacturer
before measurements. “Sensitivity” and “Shutter” parameters
were determined to have optimal values of “Sensitivity” = 75
and “Shutter” = 35, based on manufacturer’s guidelines and
after testing different parameters on the POPC vesicle sample.
Samples were diluted to an optimal concentration for analysis
(between 100 and 200 visible particles), and ∼800 μL of the
sample was injected into the measurement chamber and
measured. The device performs measurements at 11 different
positions in the measurement chamber and gives an average as
a result. Each vesicle sample was measured in triplicate to
obtain an average.
Dynamic Light Scattering. Dynamic light scattering
(DLS) being more sensitive for the detection of vesicles with
diameters below 50 nm,20 NTA data was complemented with
DLS measurements. These measurements were performed
with a ZetaSizer Nano-s (Malvern Instruments, U.K.). Each
sample is scanned at least 10 times, and the results were
averaged to present the size profile. Each vesicle sample was
measured in triplicate to obtain an average.
■ RESULTS AND DISCUSSION
Establishing a Calibration Curve. To take advantage of
the FRET assay presented in Figure 1, our approach is based
on first establishing a calibration curve using a vesicle sample
standard of known concentration and on relating the change in
the fluorescence spectrum of the FRET vesicles to the total
surface area of the sample vesicles. The total surface area of the
sample is reported as the total surface area fraction of the








where TSAFRET is the total surface area of the FRET liposomes
and TSAsample is the total surface area of the sample vesicles. In
this case, the FRET signal is reported as the fluorescence
intensity of the emission spectra at λA = 588 nm divided by the
fluorescence intensity at λD = 535 nm, where the wavelengths
are the emission peaks for rhodamine and NBD, respectively.
As further detailed in Supporting Information Section 1, the
change of the FRET signal as a function of the sample fraction
(x in eq 2) can be predicted theoretically by assuming
negligible FRET between neighboring particles in the solution
and negligible influence of liposome curvature on the FRET
signal. Under these assumptions, the system can be
approximated as a flat 2D surface and using the analytical
solution for the relative quantum yield proposed by Wolber































In eq 2, A1, A2, k1, and k2 are system independent coefficients
that have been determined numerically by Wolber and
Hudson;33,34 Y1 and Y2 are the constants related to the
spectral properties of donor and acceptor fluorophores (see SI
Section 1 for details), x is the sample fraction, and C0 is defined
as
C R c0 0
2≡ (3)
where R0 is the Förster length of the fluorophore pair and c is
the number of acceptor fluorophores per unit area.
In this work, pure POPC vesicles were chosen as the
standard for calibration curve production. This choice was
motivated by the fact that phosphocholine lipids with
asymmetric acyl chains are both the most common lipid in
eukaryotic membranes35 and frequently used in the creation of
artificial model membranes. Additionally, POPC and the dye−
lipid conjugates (NBD-PE and Rho-PE) are all phospholipids
whose concentrations in the final working solutions could be
accurately quantified orthogonally using the molybdenum blue
method for phosphorus quantification,32 thereby making it
possible to account for the potential material loss during
vesicle preparation and thus to ensure that the established
calibration curve was accurate. The acceptor fluorophore
content in the FRET liposomes was set to 0.5 mol %, i.e., in
the range where the change in FRET efficiency is most
sensitive to changes in acceptor surface density.23
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The proposed assay strategy relies on the assumption that
the maximum mixing between sample vesicles and FRET
liposomes is achieved. We therefore assessed the effect of
different sonication parameters on vesicle fusion efficiency and
chose a combination of sonication time and temperature that
ensures maximum fusion. It was determined that a minimum of
20 min of sonication time was needed for full mixing to occur
at 40 °C (Figure 2a). Conversely, the ability to fuse the vesicles
via bath sonication showed no dependency on temperature
between 20 and 80 °C (Figure 2b), indicating that a calibration
curve established at a given temperature is valid over a broad
range of sonication temperatures. Control experiments
confirmed that changes in the FRET signal upon sonication
were not an artifact of fluorophore damage (Figure S1). Thus,
the calibration curves used in this work were obtained by
sonication at 40 °C for 20 min.
A standard calibration curve displayed as the FRET signal
versus the sample fraction is shown in Figure 3A. The
experimental data was in excellent agreement with the behavior
predicted by the theoretical model, as shown by fitting the data
with eq 3 using a C0 value of 0.35 estimated from an acceptor
surface density value of 0.35 molecules/nm2, corresponding to
a rhodamine lipid concentration of 0.5 mol % and estimated
using an area-per-lipid of 0.63 nm2 36 and a Förster length (R0)
of 6.6 nm.37 Additionally, the behavior for sample fraction
values between 0.2 and 0.9 can be approximated with a linear
fit, making this curve easily usable as a calibration curve within
this range.
Using FRET liposomes (99 mol % POPC) and pure POPC
calibration vesicles, whose exact concentrations have been
verified using the phosphorous assay, it is possible to use
POPC’s area per lipid (0.63 nm2 36) to calculate both TSAFRET
and TSAsample, respectively, allowing the calibration curve to be
expressed directly as a function of the sample vesicle’s TSA
(Figure 3B). A representation on a logarithmic scale yields a
sigmoidal behavior, clearly illustrating that for the chosen
FRET liposome concentration used in this work the assay is
best-suited to quantify samples within a TSAsample range of ∼5
× 1012 to 4 × 1014 nm2, i.e., within over 2 orders of magnitude
surface area. Additionally, the sigmoidal plot allows the limit of
detection (LOD) of the assay to be more easily determined;
the LOD, i.e., the lowest quantity of analyte that can be
distinguished from the absence of it, was defined as the
TSAsample value with a signal corresponding to the mean FRET
signal of a blank sample (negative control, FRET liposomes
sonicated alone in the buffer of interest) minus the 3-fold
standard deviation of three independent measurements of the
blank signal. In our case, the LOD was found to be 9.5 × 1012
nm2, which equates to 1.18 × 108 vesicles, as estimated from
simple geometrical considerations, assuming an average vesicle
diameter of 160 nm (measured by DLS; Figure S2) and an
area-per-lipid value of 0.65 nm2.36 As the protocol is based on
60 μL of the sample solution, the LOD would correspond to a
Figure 2. Influence of sonication parameters on FRET signals. (A)
FRET signal as a function of sonication time with sonication
temperature fixed at 40 °C. (B) FRET signal as a function of
sonication temperature, with sonication time fixed at 20 min. FRET
signals are the average of three spectra obtained in independent
experiments, with standard deviation as the error.
Figure 3. Calibration curve established with POPC calibration
vesicles of known concentration. (A) Calibration curve represented as
a FRET signal (fluorescence intensity of the emission spectra at 588
nm divided by the fluorescence intensity at 535 nm) versus sample
fraction (surface area fraction of the calibration vesicles). The data
can be fitted with expression (3) (fit shown in red). Using the
following coefficients A1 = 0.6463, A2 = 0.3537, k1 = 4.7497, and k2 =
2.0618 as proposed in reference 33 for the case where the closest
distance between the donor and acceptor (Re) is much smaller than
the Förster length (R0) i.e., for Re/R0 = 0, C0 = 0.35 as estimated from
eq 3 for the FRET vesicles used here. Based on the best fit, Y1 = 1.78
and Y2 = 0.71. Additionally, the data can be fitter linearly for fractions
ranging from 0.2 to 0.9 (fit shown in green; R2 value: 0.99659). (B)
Calibration curve represented as the FRET signal versus total surface
area (TSA) of the POPC calibration vesicles. All data points are the
averages of three measurements, with standard deviations as error
bars.
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surface area concentration (SAC) of 1.64 × 1014 nm2/mL or
roughly 2.03 × 109 vesicles/mL (for vesicles with a diameter of
160 nm). It should be noted that the LOD value does not
depend on the type of material analyzed but is rather
dependent on the blank signal, resulting from sonication of
FRET vesicles and sample-free background solution. It is
therefore important to generate a calibration curve in the
appropriate background since autofluorescence, residual lipids,
or even free proteins may contribute to altering the
background signal (see SI Section 7 for more discussion).
To investigate if the performance of the assay is dependent
on vesicle size, two vesicle batches of distinct mean diameters,
i.e., mean diameters of 79 ± 0.4 and 301 ± 10 nm, were
produced. Their size distributions were measured with DLS
(Figure S2). At equal lipid concentration (as determined by
the phosphorus assay), the emission spectra of the fused
vesicles were indistinguishable (Figure 4), confirming the size
independence of the assay.
Quantification of Various Vesicle Species Using the
FRET Assay and Nanoparticle Tracking Analysis. After
having established the dependence between the FRET signal
and TSA of the sample vesicles, we demonstrated the assay’s
potential for the quantification of vesicle species of complex
composition. Specifically, samples containing extracellular
vesicles from eukaryotic cells (EVs), outer membrane vesicles
(OMVs), and the enveloped virus herpes simplex virus-2
(HSV-2) were used. The results were further compared with
NTA-based quantification. Benchmarking of the FRET-based
assay against NTA is particularly meaningful since the latter
technique allows for the determination of size distributions by
looking at particles one-by-one, which can easily be converted
into a SAC using the equation to calculate the surface area of a
sphere.
For each sample, fusion was verified by sonicating different
sample volumes. The effect of sonication temperature was
investigated between 20 and 80 °C (Figure S3). As no
statistically relevant trend was observed between temperature
and degree of mixing, all samples were sonicated at 40 °C.
Table 1 provides a summary of the various samples’ SACs
obtained using the FRET assay, mean particle diameter, NTA
quantification in particles/mL, and the conversion of the NTA
quantification data into terms of SAC, for comparison. For
comparison, the FRET-assay and NTA values obtained from
POPC liposomes are also included. The calibration curve used
for quantification in this case can be found in Figure S4, while
size distribution profiles measured with NTA are shown in
Figure S5.
As evident in Table 1 under the FRET/NTA ratio, our
results indicate that the FRET assay yielded larger SAC values
than NTA. The difference in the obtained SAC value for both
techniques was particularly striking for the POPC liposomes of
small diameter (extruded with a 30 nm pore size), where 40
times more membrane material was detected with the FRET
assay, most likely reflecting the limited ability of NTA to detect
and track vesicles with diameters below 50−70 nm.19 Indeed,
it is also important to note that the concentrations of the two
POPC samples in Table 1 were matched using the phosphorus
assay and that while the FRET assay delivered SACs with good
agreement (49.5 ± 4.5 vs 53.6 ± 6.0 nm2/mL × 1016), the
NTA delivered SACs that differed by an order of magnitude
(12.7 ± 0.6 vs 1.35 ± 0.28 nm2/mL × 1016). This further
illustrates NTA’s limited ability to accurately quantify vesicle
samples containing large fractions of smaller vesicles.
To gain insights into the precision of the assay, we
performed three independent measurements on each sample
and estimated the standard deviation and coefficient of
variation (CV = standard deviation/mean). For the FRET
Figure 4. (A) Emission spectrum after sonication (excitation
wavelength: 460 nm) for POPC vesicles of mean diameters of 79
nm (black curve) and 301 nm (red curve). The curve was obtained by
sonicating 2 μg of sample POPC vesicles with 1 μg of FRET vesicles.
(B) Average and standard deviation of the FRET signal for three
measurements. The diameter values are the averages of three
independent size measurements. Error bars for the diameter values
are the standard deviations of the distribution.
















POPC liposomes 49.5 ± 4.5 9 124 ± 52 19.8 ± 0.12 12.7 ± 0.6 4.9 3.9
(extruded with 100 nm filter)
POPC liposomes 53.6 ± 6.0 11 70 ± 30 6.6 ± 1.3 1.35 ± 0.28 21 39.4
(extruded with 30 nm filter)
OMV’s 7.22 ± 0.9 12 123 ± 49 1.9 ± 0.3 1.2 ± 0.1 8.5 6.1
HSV-2 2.21 ± 0.15 6.7 175 ± 86 0.451 ± 0.092 0.58 ± 0.23 40 3.8
EV’s 21.6 ± 1.8 8.3 126 ± 59 9.2 ± 2.3 6.3 ± 2.0 31 3.4
a± values are the standard deviation of three independent measurements, except for ± values for the diameter that are the average of the standard
deviations of the distribution of three independent measurements.
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assay, the average CV for vesicle quantification, all samples
combined, was 9.4 ± 2.1%. Such errors are similar to the ones
reported in the literature with NTA;38 however, in our hands,
CVs calculated for the NTA measurements of the different
samples showed a quite wide variation with the 100 nm
liposomes providing the best reproducibility and the complex
vesicles exhibiting a higher variance.
As with any assay, it is important to know what the
limitations are in regard to contaminants that may be present
in the sample and how they might perturb the measurement.
As this assay is based on vesicles, residual detergents in a
sample should be minimized. The presence of free protein
(e.g., BSA) was found to affect the assay by interfering with the
FRET ratio (Figure S6A); however, as most protocols for EV,
OMV, and virus isolation seek to minimize the amount of
residual free protein contamination in the sample, this effect is
most likely not significant in most cases. However, it is
important to gauge the effect of density gradient mediums such
as sucrose and Optiprep or of the commonly used
cryoprotectant glycerol. Neither sucrose, Optiprep, nor
glycerol were found to alter the assay’s ability to quantify a
vesicle sample (Figure S6A).
If significant levels of free protein are believed to be in a
sample or any other contaminant that is feared could interfere
with the quantification, then the creation of a calibration curve
using a background diluent that contains the suspected
contaminants is of course the best strategy to take the effects
of those contaminants into account. Additionally, it is advisable
to always measure an unknown sample at two different
dilutions that fall within the calibration curve range to verify
that the sample does not show signs of interfering
contaminants.
■ CONCLUSIONS
In this work, we have developed and validated a FRET-based
method to quantify the total surface area of membranes in a
purified vesicle sample. This method relies on altering the
emission spectrum of a fluorophore pair subject to FRET
through the sonication-induced fusion of vesicles containing a
FRET pair and nonlabeled sample vesicles. An advantage of
this assay is that it can be performed without any specialized
instrumentation; just a relatively cheap bath sonicator and a
spectrofluorometer, generic instruments commonly found in
biochemistry labs, are sufficient for its execution. As predicted
theoretically, the FRET signal is dependent on the sample
fraction, making it possible to quantify membrane surface area
in a sample over several orders of magnitude after establishing
a calibration curve. With the experimental parameters used
here, and without extensive assay optimization, we were able to
achieve a limit of detection of approximately 108 particles (109
particles/mL); a lower LOD could potentially be obtained
using a lower concentration of FRET liposomes, thereby
shifting the dynamic range of the assay, the limiting factor
being the sensitivity of the spectrofluorometer. Additionally,
the performance of the assay could be further improved by
choosing an optimal fluorophore pair. Our theoretical model
suggests that the method sensitivity can be improved by
maximizing the value of C0 and Y1, yielding the steepest decay.
This can be achieved by choosing a FRET pair with a larger
Förster radius (R0) and where the acceptor has a high quantum
yield and with a narrow emission spectrum.
The assay performance was further compared to that of
nanoparticle tracking analysis, a well-established method for
particle number quantification and size determination,16
making a comparison of surface area concentrations partic-
ularly straightforward. A major advantage of our assay as
compared to methods relying on the imaging of individual
vesicles in scattering mode, such as NTA, is that its
performance is independent of vesicle size, making it very
well-suited to characterize polydisperse samples containing
small vesicles (<70 nm). Indeed, it has been previously
reported that the visualization of lipid vesicles using NTA
devices is particularly challenging due to the vesicle’s weak
scattering properties in aqueous solution, typically limiting
detection to vesicles larger than ∼50 nm in diameter.19 Our
assay was also found to be somewhat superior to NTA in terms
of dynamic range, as it allows for direct quantification for
vesicle concentrations spanning over 2 orders of magnitude, as
compared to the rather limited dynamic range of some NTA
instruments (less than 1 order of magnitude).21,39−41
In terms of the lowest concentration that can be quantified,
we report here an LOD value of ∼109 particles/mL, i.e., 1−2
orders of magnitude higher than that reported in the literature
for ZetaView NTA measurements of vesicle samples39,40
although it cannot be excluded that these concentrations are
underestimated, in the likely case that the smallest vesicles in
the population are too small to be detected. Since our assay is
size-independent, it can therefore be said that in terms of both
LOD and the total amount of material needed to carry out a
lipid vesicle quantification, the performance of both techniques
is roughly comparable. It should however further be high-
lighted that the FRET-based assay can be carried out at much
lower sample volumes (with the protocol presented here, 58
μL of the sample is sufficient), while according to the
provider’s specifications, 500 μL of samples is needed to carry
out an accurate quantification with the ZetaView,42 making the
FRET-based assay of advantage when low amounts of starting
material are available.
In spite of the fact that vesicles of complex composition,
from both biological and synthetic origins, are associated with
such a broad spectrum of research areas, methods to quantify
lipid vesicle concentrations in a robust and versatile manner
are surprisingly underdeveloped. While expressing the
concentration of a vesicle sample in terms of SAC is
unconventional, this measure provides a competitive alter-
native or complement to expressing vesicle concentration in
number of particles/milliliter. Although this assay cannot
decouple size from particle numbers, as is the case for NTA, it
provides an unambiguous and size-independent quantification
of the total amount of membrane material present in a sample.
This may be of advantage when studying the biological effect
of different EV batches or the efficiency of a liposome-based
drug delivery system, where dosing the same total amount of
material may be preferred to dosing the same number of
particles, which may have significantly different size distribu-
tions. Also, it should be noted that this method is unspecific, in
that it does not distinguish vesicle subpopulations according to
any biomolecular identity (i.e., the presence of a specific
marker on its surface or within its lumen). Rather, it relies on
vesicle purification prior to analysis. However, the assay’s
ability to better quantify subpopulations of vesicles with
diameters below 100 nm attained from purification protocols
including size exclusion chromatography, differential centrifu-
gation, or affinity chromatography to select vesicles of desired
size, density, or composition is likely to make it a powerful
quantitative tool in a variety of contexts.
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